tailieunhanh - Prescribing of long-acting beta-2-agonists/inhaled corticosteroids after the SMART trial

After the SMART trial evaluating the safety of salmeterol (long-acting beta-2-agonist (LABA)) in asthma patients, regulatory actions were taken to promote a guideline-adherent prescribing of LABA only to patients receiving inhaled corticosteroids (ICS). We aim to analyse LABA- and ICS-related prescription patterns after the SMART trial in Germany. |

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN